Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis
Authors
Keywords
-
Journal
PROSTATE
Volume 82, Issue 16, Pages 1483-1490
Publisher
Wiley
Online
2022-09-12
DOI
10.1002/pros.24413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial.
- (2021) Paul Vincent Viscuse et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adding carboplatin to chemotherapy regimens for metastatic castrate‐resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes
- (2020) Mohamed E. Ahmed et al. PROSTATE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients
- (2019) Nicolas Plouznikoff et al. ANNALS OF NUCLEAR MEDICINE
- Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
- (2019) Florian Handle et al. Scientific Reports
- Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
- (2019) Andrew J. Armstrong et al. JAMA Oncology
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
- (2018) William T. Lowrance et al. JOURNAL OF UROLOGY
- Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
- (2017) Anna Katharina Seitz et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
- (2017) A H Bryce et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Emerging Variants of Castration-Resistant Prostate Cancer
- (2017) Panagiotis J. Vlachostergios et al. Current Oncology Reports
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
- (2015) Howard I. Scher et al. PLoS One
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
- (2014) John M. Fitzpatrick et al. EUROPEAN JOURNAL OF CANCER
- Operational Characteristics of 11C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial Treatment
- (2012) Christopher R. Mitchell et al. JOURNAL OF UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
- (2011) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started